Evidence map›Paper›PMID 30368590›Full record

ArticleAnnals of hematology2019

Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia.

Kristina Zaprazna, Kamila Reblova, Veronika Svobodova, Lenka Radova, Vojtech Bystry, Jiri Baloun, Kristina Durechova, Nikola Tom, Tomas Loja, Martina Buresova and 7 more

Open access · greenAbstract read
In one paragraph

Article in Annals of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Kristina ZapraznaCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic. kzaprazna@gmail.com.
Kamila ReblovaCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Veronika SvobodovaCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Lenka RadovaCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Vojtech BystryCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Jiri BalounCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Kristina DurechovaDepartment of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Nikola TomCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Tomas LojaCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Martina BuresovaCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Kamila StranskaCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Alexandra OltovaDepartment of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Michael DoubekCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Michael L AtchisonDepartment of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Martin TrbusekDepartment of Internal Medicine - Hematology and Oncology, Faculty of Medicine, Masaryk University and University Hospital Brno, Brno, Czech Republic.
Jitka MalcikovaCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic.
Sarka PospisilovaCentral European Institute of Technology, Center of Molecular Medicine, Masaryk University, Kamenice 5/A35, 625 00, Brno, Czech Republic. pospisilova.sarka@fnbrno.cz.
Central European Institute of Technology · CZMasaryk University · CZUniversity Hospital Brno · CZUniversity of Pennsylvania · US

Funding

Control of B cell Development by YY1R01AI079002 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ATCHISON, MICHAEL LEE · 2010 to 2020
$4.3M
JCMM - Somopro No. 3SGA5792MEYS CR CEITEC 2020 (LQ1601)MEYS CR LM2011020NIAID NIH HHS R01 AI079002
6 · The paper itself

Abstract

Activation-induced cytidine deaminase (AID) is a mutator enzyme essential for somatic hypermutation (SHM) and class switch recombination (CSR) during effective adaptive immune responses. Its aberrant expression and activity have been detected in lymphomas, leukemias, and solid tumors. In chronic lymphocytic leukemia (CLL) increased expression of alternatively spliced AID variants has been documented. We used real-time RT-PCR to quantify the expression of AID and its alternatively spliced transcripts (AIDΔE4a, AIDΔE4, AIDivs3, and AIDΔE3E4) in 149 CLL patients and correlated this expression to prognostic markers including recurrent chromosomal aberrations, the presence of complex karyotype, mutation status of the immunoglobulin heavy chain variable gene, and recurrent mutations. We report a previously unappreciated association between higher AID transcript levels and trisomy of chromosome 12. Functional analysis of AID splice variants revealed loss of their activity with respect to SHM, CSR, and induction of double-strand DNA breaks. In silico modeling provided insight into the molecular interactions and structural dynamics of wild-type AID and a shortened AID variant closely resembling AIDΔE4, confirming its loss-of-function phenotype.

Indexed as

Alternative SplicingCytidine DeaminaseGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticLeukemia, Lymphocytic, Chronic, B-CellModels, BiologicalNeoplasm ProteinsTrisomyAgedAICDA (Activation-Induced Cytidine Deaminase)AnimalsChromosomes, Human, Pair 12Computer SimulationFemaleHumansMaleAICDA (Activation-Induced Cytidine Deaminase)Cytidine DeaminaseNeoplasm ProteinsActivation induced deaminaseAlternative splicingChronic lymphocytic leukemiaComplex karyotypeTrisomy 12

Identifiers

PMID30368590
PMCPMC8923156
OpenAlexW2898567312

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.